Penn Medicine Amyloidosis Program | oneAMYLOIDOSISvoice
Academic & Health Care Centers

Penn Medicine Amyloidosis Program

3400 Spruce Street
Philadelphia, Pennsylvania, United States
Phone   Web  

The Amyloidosis Program at Penn Medicine is involved in the treatment and diagnosis of amyloidosis and the development of new drugs to treat the disease and its variants. Amyloidosis can have a variety of causes, and as a result, the Program brings together specialists from cardiology, nephrology, hematology-oncology, neurology, rheumatology, pulmonology and organ transplantation.

The Penn Amyloidosis Program is involved in the development of a promising new drug called NEOD001, which is designed to target and remove the buildup of amyloids in the heart and other affected organs. So far, the majority of patients in the study have seen stability or improvement in the blood tests that measure the impact of amyloidosis on the heart. The primary investigator for the NEOD001 study at Penn Medicine, Brendan Weiss, MD, director of the Penn Amyloidosis Program, is enthusiastic about the preliminary results.

The team includes healthcare professionals in the following areas:

Hematology and Oncology:
Adam D. Cohen, MD

Hansie M. Mathelier, MD, FACC

Sami L. Khella, MD

Laura M. Dember, MD


The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.